These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
219 related articles for article (PubMed ID: 22533828)
1. Juxtaglomerular apparatus hyperplasia under dual angiotensin blockade. A footprint of adequate RAS inhibition or a concern for renal fibrosis? Fernandez-Fernandez B; Ortiz A; Gomez-Guerrero C; Barat A; Martín-Cleary C; Egido J BMC Nephrol; 2012 Apr; 13():21. PubMed ID: 22533828 [TBL] [Abstract][Full Text] [Related]
2. Resistant Hypertension On Treatment (ResHypOT): sequential nephron blockade compared to dual blockade of the renin-angiotensin-aldosterone system plus bisoprolol in the treatment of resistant arterial hypertension - study protocol for a randomized controlled trial. Cestário EDES; Fernandes LAB; Giollo-Júnior LT; Uyemura JRR; Matarucco CSS; Landim MIP; Cosenso-Martin LN; Tácito LHB; Moreno H; Vilela-Martin JF; Yugar-Toledo JC Trials; 2018 Feb; 19(1):101. PubMed ID: 29433578 [TBL] [Abstract][Full Text] [Related]
3. Detrimental effect of renin-angiotensin blockade on progression of chronic kidney disease at later stages: A matter of dosage adjustment? Caravaca-Fontán F; Valladares J; Díaz-Campillejo R; Barroso S; Luna E; Caravaca F Nefrologia (Engl Ed); 2020; 40(1):38-45. PubMed ID: 31196659 [TBL] [Abstract][Full Text] [Related]
4. New approaches to blockade of the renin-angiotensin-aldosterone system: evidence from randomized controlled trials (RCTs) of angiotensin-converting enzyme inhibitors and angiotensin II-receptor blockers--questions remain unsolved. Ueda S J Pharmacol Sci; 2010; 113(4):292-5. PubMed ID: 20675956 [TBL] [Abstract][Full Text] [Related]
5. Is there benefit in dual renin-angiotensin-aldosterone system blockade? No, yes and maybe: a guide for the perplexed. Wong J Diab Vasc Dis Res; 2013 May; 10(3):193-201. PubMed ID: 23349369 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Dual Blockade of the Renin-Angiotensin-Aldosterone System in Diabetic Kidney Disease: A Meta-Analysis. Feng Y; Huang R; Kavanagh J; Li L; Zeng X; Li Y; Fu P Am J Cardiovasc Drugs; 2019 Jun; 19(3):259-286. PubMed ID: 30737754 [TBL] [Abstract][Full Text] [Related]
7. Angiotensin receptor blockers are associated with lower mortality than ACE inhibitors in predialytic stage 5 chronic kidney disease: A nationwide study of therapy with renin-angiotensin system blockade. Lin CC; Wu YT; Yang WC; Tsai MJ; Liu JS; Yang CY; Li SY; Ou SM; Tarng DC; Hsu CC PLoS One; 2017; 12(12):e0189126. PubMed ID: 29216260 [TBL] [Abstract][Full Text] [Related]
8. [Is there still a place for a dual blockade of the renin-angiotensin system in 2012?]. Krzesinski JM; Scheen AJ Rev Med Suisse; 2012 Aug; 8(351):1598-603. PubMed ID: 22988713 [TBL] [Abstract][Full Text] [Related]
9. The reno-protective effect of the dual blockade of the renin angiotensin system (RAS). Luno J; Praga M; de Vinuesa SG Curr Pharm Des; 2005; 11(10):1291-300. PubMed ID: 15853685 [TBL] [Abstract][Full Text] [Related]
10. FGF-23 in untreated nephrotic syndrome and effects of the renin-angiotensin-aldosterone system. Pazianas M Nephrology (Carlton); 2019 Feb; 24(2):273. PubMed ID: 30697887 [No Abstract] [Full Text] [Related]
11. Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials. Makani H; Bangalore S; Desouza KA; Shah A; Messerli FH BMJ; 2013 Jan; 346():f360. PubMed ID: 23358488 [TBL] [Abstract][Full Text] [Related]
12. The molecular basis of increased glomerulosclerosis after blockade of the renin angiotensin system in growth hormone transgenic mice. Peten EP; Striker LJ; Fogo A; Ichikawa I; Patel A; Striker GE Mol Med; 1994 Nov; 1(1):104-15. PubMed ID: 8790606 [TBL] [Abstract][Full Text] [Related]
13. Effect of dual compared to no or single renin-angiotensin system blockade on risk of renal replacement therapy or death in predialysis patients: PREPARE-2 study. Voskamp PWM; Dekker FW; van Diepen M; Hoogeveen EK; J Am Soc Hypertens; 2017 Oct; 11(10):635-643. PubMed ID: 28802945 [TBL] [Abstract][Full Text] [Related]
14. Competing Effects of Renin Angiotensin System Blockade and Sodium-Glucose Cotransporter-2 Inhibitors on Erythropoietin Secretion in Diabetes. Marathias KP; Lambadiari VA; Markakis KP; Vlahakos VD; Bacharaki D; Raptis AE; Dimitriadis GD; Vlahakos DV Am J Nephrol; 2020; 51(5):349-356. PubMed ID: 32241009 [TBL] [Abstract][Full Text] [Related]
15. Recent changes in the landscape of combination RAS blockade. Epstein BJ; Smith SM; Choksi R Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020 [TBL] [Abstract][Full Text] [Related]
16. To RAS or not to RAS? The evidence for and cautions with renin-angiotensin system inhibition in patients with diabetic kidney disease. St Peter WL; Odum LE; Whaley-Connell AT Pharmacotherapy; 2013 May; 33(5):496-514. PubMed ID: 23576066 [TBL] [Abstract][Full Text] [Related]
17. Effects of Renin-Angiotensin-Aldosterone System Blockade in Patients with End-Stage Renal Disease. Slomka T; Lennon ES; Akbar H; Gosmanova EO; Bhattacharya SK; Oliphant CS; Khouzam RN Am J Med Sci; 2016 Mar; 351(3):309-16. PubMed ID: 26992264 [TBL] [Abstract][Full Text] [Related]
18. Renin-angiotensin-aldosterone system inhibitors in heart failure. Shearer F; Lang CC; Struthers AD Clin Pharmacol Ther; 2013 Oct; 94(4):459-67. PubMed ID: 23852393 [TBL] [Abstract][Full Text] [Related]
19. Dual Blockade of the Renin-Angiotensin System: A Strategy that Should Be Reconsidered in Cardiorenal Diseases? Mei M; Zhou Z; Zhang Q; Chen Y; Zhao H; Shen B Nephron; 2021; 145(2):99-106. PubMed ID: 33550292 [TBL] [Abstract][Full Text] [Related]
20. Effect of a triple blockade of the renin-angiotensin-system in recurrent focal segmental glomerulosclerosis after kidney transplantation. Freiberger V; Amann K; Heemann U; Frank H Transpl Int; 2009 Nov; 22(11):1110-3. PubMed ID: 19497068 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]